NASDAQ:KLTO Klotho Neurosciences (KLTO) Stock Price, News & Analysis $0.17 +0.01 (+8.24%) As of 04/25/2025 03:57 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock About Klotho Neurosciences Stock (NASDAQ:KLTO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Klotho Neurosciences alerts:Sign Up Key Stats Today's Range$0.15▼$0.1850-Day Range$0.15▼$0.3852-Week Range$0.11▼$11.05Volume118,724 shsAverage Volume604,222 shsMarket Capitalization$4.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Read More… Receive KLTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Klotho Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KLTO Stock News HeadlinesKlotho Neurosciences faces Nasdaq delisting riskApril 23 at 10:06 AM | investing.comKlotho Neurosciences to Acquire SkyBell Tech SubsidiaryApril 3, 2025 | investing.comTrump’s Secret Social Security Plan?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 26, 2025 | Paradigm Press (Ad)Klotho Neurosciences, Inc. (KLTO)February 2, 2025 | ca.finance.yahoo.comKlotho Neuroscience Inc (KLTO)January 28, 2025 | investing.comKlotho Neurosciences secures $2M in convertible notes and warrantsJanuary 24, 2025 | msn.comKlotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San FranciscoJanuary 8, 2025 | globenewswire.comDr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory BoardDecember 9, 2024 | globenewswire.comSee More Headlines KLTO Stock Analysis - Frequently Asked Questions How have KLTO shares performed this year? Klotho Neurosciences' stock was trading at $0.4850 at the beginning of the year. Since then, KLTO shares have decreased by 64.5% and is now trading at $0.1721. View the best growth stocks for 2025 here. How were Klotho Neurosciences' earnings last quarter? Klotho Neurosciences, Inc. (NASDAQ:KLTO) announced its quarterly earnings data on Monday, March, 31st. The company reported ($0.07) earnings per share (EPS) for the quarter. How do I buy shares of Klotho Neurosciences? Shares of KLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/31/2025Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KLTO Previous SymbolNASDAQ:KLTO CIK1907223 Webwww.klothoneuro.com Phone(833) 931-6330FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1.35 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-25.89% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.18 per share Price / Cash Flow0.95 Book Value($2.16) per share Price / Book-0.08Miscellaneous Outstanding Shares28,011,000Free Float26,539,000Market Cap$4.82 million OptionableN/A BetaN/A 20 Stocks to Sell NowGet This Free Report This page (NASDAQ:KLTO) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDeepSeek’s Clear and Present DangerDeepSeek — the alleged “$5.5 million” AI project — isn’t an open-source breakthrough. It’s a Trojan horse.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.